Replies to post #104256 on NorthWest Biotherapeutics Inc (NWBO)

[AVII77]

The only difference with RANO is it introduced non-enhanced lesions! Hello, T2/FLAIR.

That's not all. And you are ignoring the relevant additional motivation for RANO.

From the JCO RANO paper

"The limitations of the Macdonald Criteria have become even more apparent with the increased incidence of pseudoprogression in patients receiving radiotherapy with temozolomide and the recent introduction of antiangiogenic therapies that affect the permeability of tumor vasculature. This has led to the current effort to revise the response criteria for high-grade gliomas.17 The major issues are discussed in the following sections."

So, again I ask you. If there were no "limitations" of the Macdonald criteria to address psPD as you assert, why did RANO introduce changes to address it?

Macdonald was from 1990.
psPD increased after Temodar and concurrent chemorad became used in the mid 2000's
RANO not only addressed avastin issues, it also addressed the psPD issue.

Be honest with yourself and others on this point.